Please assess the completion status of the following clinical trial:

Trial Title: DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets 1 of the following criteria:~  * Histologically and/or cytologically confirmed stage IV adenocarcinoma of the breast (patient)~ * No diagnosis of an abnormal breast biopsy (including atypical ductal or lobular hyperplasia), or new diagnosis of breast cancer or breast cancer recurrence within the past five years (healthy participant)~* Evidence of disease progression AND initiating a new systemic treatment regimen with trastuzumab (Herceptin®), chemotherapy, endocrine therapy, or investigational agent(s) (patient)~  * Treatment may be given as a single agent or in combination~* Measurable or evaluable disease (patient)~  * Measurable disease is defined as ≥ 1 measurable lesion identified by RECIST criteria~ * Patients with evaluable disease only must have ≥ 1 tumor marker (e.g., carcinoembryonic antigen, CA 27-29, or CA 15-3) above normal level~* Treated brain metastases (surgery or radiation therapy) allowed provided patient has evidence of disease stability or presence of other site(s) of measurable or evaluable disease (patient)~  * No leptomeningeal disease~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Female~* Menopausal status not specified~* ECOG performance status 0-2~* No known cancer within the past 5 years other than basal cell or squamous cell carcinoma of the skin and/or adequately treated cervical cancer (healthy participant)~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior therapy in the preoperative, adjuvant, and/or metastatic setting allowed~  * Any number of prior regimens in any setting allowed~* No prior radiation therapy to the only site of disease unless there is evidence of post-radiation disease progression~* No selective estrogen receptor modulator or aromatase inhibitor for breast cancer prevention or therapy within the past 12 months (healthy participant)~* Prior or concurrent use of raloxifene for osteopenia or osteoporosis therapy allowed (healthy participant)~* Concurrent participation in another clinical trial, including one involving an investigational agent(s), allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Metastatic breast cancer patients (Type: None): DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).